Hemodiyaliz Hastalarında Sinakalsetin Serum Kalsiyum, Fosfor, ve Paratiroid Hormon Düzeylerine Etkisi

Yıl 2012, Cilt: 1 Sayı: 2, 55 - 60, 01.05.2012

Erkan Şengül Selma Satılmışoğlu Aysun Şengül Sevim Dindar

https://doi.org/10.5505/abantmedj.2012.03522

Öz

Bu çalışmanın amacı hemodiyaliz hastalarında sinakalset kullanımının serum kalsiyum, fosfor ve paratiroid hormon üzerideki etkisini incelemektir. YÖNTEMLER: Çalışma, 15 9 E, 6 K hemodiyaliz hastasında yapıldı. 3 ay süre ile sinakalset kullanan hastaların retrospektif olarak dosyaları incelendi. Biyokimya tetkikleri ve kan basıncı kayıtları kaydedildi. İstatistiksel analizler SPSS ver. 15 ile gerçekleştirildi.BULGULAR: Serum kalsiyum, kalsiyum x fosfor ürünü ve paratiroid hormon düzeylerinde istatistiksel olarak anlamlı azalmalar saptandı sırasıyla P=0.001, P=0.04 ve P=0.009 . Fosfor düzeyi azalmakla birlikte farklılık istatistiksel olarak anlamlı bulunmadı. Üç hastada bulantı, üç hastada ise bulantı ve kusma gözlendi. Ayrıca üç hastada kalsiyum seviyesi 8 mg/dl’nin altına düştü. SONUÇ: Sinakalset hemodiyaliz hastalarında serum kalsiyum, kalsiyum x fosfor ürünü ve paratiroid hormon düzeylerini anlamlı olarak azaltmaktadır. Tedavi sırasında bulantı, kusma ve hipokalsemi sık görülmektedir. Ancak, daha fazla hasta üzerinde yapılacak çalışmalara ihtiyaç vardır.

Anahtar Kelimeler

Hiperparatiroidizm, sinakalset, hemodiyaliz

The effect of Cinacalcet on Serum Calcium, Phosphorus and Parathyroid Hormone in Hemodialysis Patients

Öz

The purpose of this study is to examine the effect of cinacalcet on serum calcium, phosphorus, and parathyroid hormone in hemodialysis patients.METHODS: This study was performed in 15 hemodialysis patients. The medical records of patients taking cinacalcet for three months were examined. Biochemical tests and blood pressure were recorded. The statistical analysis was performed using SPSS version 15.0. P< 0.05 was considered statistically significant. RESULTS: There were statistically significant decreases in calcium, calcium x phosphorus product and parathyroid hormone levels P=0.001, P=0.04 and P=0.009 respectively . Phosphorus level was reduced but not significantly. Nausea was observed in three patients, nausea and vomiting in three patients, as well as hypocalcaemia

Anahtar Kelimeler

Hyperparathyroidism, cinacalcet, hemodialysis

Kaynakça

• Moe SM, Drüeke T, Lameire N, Eknoyan G. Chronic kidney disease-mineral-bone disorder: a new paradigm. Adv Chronic Kidney Dis 2007; 14: 3-12.
• Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and mor- bidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208–2218.
• Manley HJ, Garvin CG, Drayer DK, Reid GM, Bender WL, Neufeld TK, Hebbar S, Muther RS. Medication prescrib- ing patterns in ambulatory haemodialysis patients: comparisons of USRDS to a large not-for-profit dialysis provider. Nephrol Dial Transplant 2004; 19: 1842–1848.
• Komaba H, Tanaka M, Fukagawa M. Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Inter Med 2008; 47: 989-994.
• Nagano N. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroid- ism. Pharmacol Ther 2006; 109: 339–365.
• Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Ol- son KA, Drüeke TB, Goodman WG. Cinacalcet for sec- ondary yperparathyroidism in patients receiving hemo- dialysis. N Engl J Med 2004; 350: 1516–1525.
• Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), CaxPO(4) product, and parathyroid hormone with cardiac mortali ty risk in chronic haemodialysis patients. J Am Soc Nephrol 2001;12: 2131–2138.
• Noordzij M, Korevaar JC, Boeschoten EW, Dekker FW, Bos WJ, Krediet RT. The K/DOQI guideline for bone me- tabolism and disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis 2005; 46: 925–932.
• London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC. Arterial calcifications and bone his- tomorphometry in end-stage renal disease. J Am Soc Nephrol 2004; 15: 1943–1951.
• Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis pa- tients. Am J Kidney Dis 1996; 27: 394–401.
• Wang AY, Wang M, Woo J, Lam CW, Li PK, Lui SF, Sand- erson JE. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol 2003; 14: 159–168.
• Moe SM, O'Neill KD, Duan D, Ahmed S, Chen NX, Leap- man SB, Fineberg N, Kopecky K. Medial artery calcifica- tion in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 2002; 61: 638–647.
• National Kidney Foundation: K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 2003 (suppl 3); 42: S1- S202.
• Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483.
• Goodman WG. Recent developments in the manage- ment of secondary hyperparathyroidism. Kidney Int 2001; 59: 1187–1201.
• Messa P, Macario F, Yaqoob M, et al. Assessing a New Cinacalcet (Sensipar/Mimpara) Treatment Algorithm for Secondary Hyperparathyroidism. Clin J Am Soc Nephrol 2008; 3: 36–45.
• Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD, Albizem MB, Coburn JW. Cinacalcet HCl, an oral cal- cimimetic agent for the treatment of secondary hy- perparathyroidism in hemodialysis and peritoneal dialy- sis: A randomized double-blind, multicenter study. J Am Soc Nephrol 2005; 16: 800–807.
• Fishbane S, Shapiro WB, Corry DB, Vicks SL, Roppolo M, Rappaport K, Ling X, Goodman WG, Turner S, Charytan C. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol 2008; 3: 1718-1725.